-
1
-
-
38549099015
-
Pharmacologic treatments for opioid dependence: Detoxification and maintenance options
-
Kleber H. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci 2007;9:455-470.
-
(2007)
Dialogues Clin. Neurosci.
, vol.9
, pp. 455-470
-
-
Kleber, H.1
-
2
-
-
33750464502
-
Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in st. Petersburg, russia
-
Krupitsky EM, Zvartau EE, Masalov DV, et al. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat 2006;31:319-328.
-
(2006)
J. Subst Abuse Treat
, vol.31
, pp. 319-328
-
-
Krupitsky, E.M.1
Zvartau, E.E.2
Masalov, D.V.3
-
3
-
-
33846096441
-
Sustained-release naltrexone formulations for the treatment of alcohol and opioid dependence
-
Volpicelli RG, Fenton M. Sustained-release naltrexone formulations for the treatment of alcohol and opioid dependence. Future Neurol 2006;1:389-398.
-
(2006)
Future Neurol.
, vol.1
, pp. 389-398
-
-
Volpicelli, R.G.1
Fenton, M.2
-
4
-
-
36348931537
-
Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence
-
Dunbar JL, Turncliff RZ, Hayes SC, et al. Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence. J Stud Alcohol Drugs 2007;68:862-870.
-
(2007)
J. Stud Alcohol Drugs
, vol.68
, pp. 862-870
-
-
Dunbar, J.L.1
Turncliff, R.Z.2
Hayes, S.C.3
-
5
-
-
32244444572
-
Injectable, sustained-release naltrexone for the treatment of opioid dependence
-
Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence. Arch Gen Psychiatry 2006;63:210-218.
-
(2006)
Arch. Gen. Psychiatry
, vol.63
, pp. 210-218
-
-
Comer, S.D.1
Sullivan, M.A.2
Yu, E.3
-
6
-
-
33644771227
-
Single-and multiple-dose pharmacokinetics of Long-acting injectable naltrexone
-
Dunbar JL, Turncliff RZ, Dong Q, et al. Single-and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res 2006;30: 480-490.
-
(2006)
Alcohol Clin. Exp. Res.
, vol.30
, pp. 480-490
-
-
Dunbar, J.L.1
Turncliff, R.Z.2
Dong, Q.3
-
7
-
-
47549113312
-
Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone
-
This clinical case demonstrates that it is possible to overcome opioid blockade with Vivitrol and precipitate withdrawal in some circumstances
-
Fishman M. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. Addiction 2008;103:1399-1401. This clinical case demonstrates that it is possible to overcome opioid blockade with Vivitrol and precipitate withdrawal in some circumstances.
-
(2008)
Addiction
, vol.103
, pp. 1399-1401
-
-
Fishman, M.1
-
8
-
-
34250353080
-
Overcoming opioid blockade from depot naltrexone (prodetoxon®)
-
Kruptisky EM, Burakov AM, Tsoy MV, et al. Overcoming opioid blockade from depot naltrexone (Prodetoxon®). Addiction 2007;102:1164-1165.
-
(2007)
Addiction
, vol.102
, pp. 1164-1165
-
-
Kruptisky, E.M.1
Burakov, A.M.2
Tsoy, M.V.3
-
9
-
-
34447282259
-
A 'biorelevant' approach to accelerated in vitro drug release testing of a biodegradable, naltrexone implant
-
Iyer SS, Barr WH, Karnes HT. A 'biorelevant' approach to accelerated in vitro drug release testing of a biodegradable, naltrexone implant. Int J Pharm 2007;340 (1-2) :119-125.
-
(2007)
Int. J. Pharm.
, vol.340
, Issue.1-2
, pp. 119-125
-
-
Iyer, S.S.1
Barr, W.H.2
Karnes, H.T.3
-
10
-
-
34447251651
-
A 'biorelevant' system to investigate in vitro drug released from a naltrexone implant
-
IyerSS, Barr WH, Dance ME, et al. A 'biorelevant' system to investigate in vitro drug released from a naltrexone implant. Int J Pharm 2007;340 (1-2) :104-118.
-
(2007)
Int. J. Pharm.
, vol.340
, Issue.1-2
, pp. 104-118
-
-
Iyer, S.S.1
Barr, W.H.2
Dance, M.E.3
-
13
-
-
77952243821
-
The Long term use of prodetoxone in the treatment of opiate dependence
-
Russian
-
Boiko EO. The long term use of Prodetoxone in the treatment of opiate dependence. Narcologiya (Addict Med) 2007;3:21-24. (in Russian).
-
(2007)
Narcologiya (Addict Med)
, vol.3
, pp. 21-24
-
-
Boiko, E.O.1
-
14
-
-
38549097156
-
Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program
-
Reece AS. Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy 2007;2:35.
-
(2007)
Subst Abuse Treat Prev Policy
, vol.2
, pp. 35
-
-
Reece, A.S.1
-
15
-
-
70349667302
-
Improving clinical outcomes in treating heroin dependence
-
This first double-blind, placebo-controlled, randomized clinical trial showed the effectiveness of a single dose of the Australian naltrexone implant in comparison with oral naltrexone
-
Hulse GK, Morris N, Arnold-Reed D, et al. Improving clinical outcomes in treating heroin dependence. Arch Gen Psychiatry 2009;66:1108-1115. This first double-blind, placebo-controlled, randomized clinical trial showed the effectiveness of a single dose of the Australian naltrexone implant in comparison with oral naltrexone.
-
(2009)
Arch. Gen. Psychiatry
, vol.66
, pp. 1108-1115
-
-
Hulse, G.K.1
Morris, N.2
Arnold-Reed, D.3
-
16
-
-
67649207399
-
Naltrexone implants after in-patient treatment for opioid dependence: Randomized controlled trial
-
This study done in Norway compares oral naltrexone and Australian implantable naltrexone
-
Kunoe N, Lobmaier P, Vederhus JK, et al. Naltrexone implants after in-patient treatment for opioid dependence: randomized controlled trial. Br J Psychiatry 2009;194:541-546. This study done in Norway compares oral naltrexone and Australian implantable naltrexone.
-
(2009)
Br. J. Psychiatry
, vol.194
, pp. 541-546
-
-
Kunoe, N.1
Lobmaier, P.2
Vederhus, J.K.3
-
18
-
-
69349084677
-
Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine
-
Reece AS. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine. J Subst Abuse Treat 2009;37:256-265.
-
(2009)
J. Subst Abuse Treat
, vol.37
, pp. 256-265
-
-
Reece, A.S.1
-
19
-
-
42049087623
-
Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance therapy or naltrexone implantation
-
Ngo HTT, Tait RJ, Hulse GK. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance therapy or naltrexone implantation. Arch Gen Psychiatry 2008;65:457-465.
-
(2008)
Arch. Gen. Psychiatry
, vol.65
, pp. 457-465
-
-
Ngo, H.T.T.1
Tait, R.J.2
Hulse, G.K.3
-
20
-
-
47349122953
-
Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment
-
Tait RG, Ngo HTT, Hulse GH. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. J Subst Abuse Treat 2008;35: 116-124.
-
(2008)
J. Subst Abuse Treat
, vol.35
, pp. 116-124
-
-
Tait, R.G.1
Ngo, H.T.T.2
Hulse, G.H.3
-
21
-
-
36549041776
-
Depot naltrexone use for opioid dependence in Australia: Large-scale use of an unregistered medication in the absence of data on safety and efficacy
-
Degenhardt L, Gibson A, Mattick RP, et al. Depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy. Drug Alcohol Rev 2008;27:1-3.
-
(2008)
Drug Alcohol Rev.
, vol.27
, pp. 1-3
-
-
Degenhardt, L.1
Gibson, A.2
Mattick, R.P.3
|